← Retour au Screener

Sector: Santé
Open in Terminal → VKTXLive chart · Key metrics · News · Smart money

Viking Therapeutics

VKTX Mid Cap

Healthcare · Biotechnology

Mis à jour: Jun 18, 2026, 22:21 UTC

26,48 €
+0.3% aujourd'hui
52W: 20,02 € – 37,62 €
52W Low: 20,02 € Position: 36.8% 52W High: 37,62 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
3,1 Md €
Capitalisation boursière
Croissance du CA
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-70.04%
Rentabilité des capitaux propres
Beta
0.68
Sensibilité au marché
Positions vendeuses
20.37%
% du flottant vendu à découvert
Volume moyen
2,176,787
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Achat Fort
19 analysts
Avg. Price Target
80,71 €
+204.74% upside
Target Range
29,64 € – 108,97 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 59 Exchange: NCM

Viking Therapeutics en bref

Viking Therapeutics (VKTX) is currently trading at 26,48 € with a market capitalization of 3,1 Md €. The 52-week range spans from 20,02 € to 37,62 €; the current price is 29.6% below the yearly high.

💰 Dividende

Viking Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

19 analystes évaluent Viking Therapeutics (VKTX) au consensus : Achat Fort. L'objectif de cours moyen est de 80,71 €, soit un potentiel de +204.74% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 29,64 € à 108,97 €.

Viking Therapeutics : la thèse d'investissement en détail

Viking Therapeutics (VKTX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 204.74% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Short interest sits at 20.37% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

  • The analyst consensus price target implies 204.74% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Strong Buy
Points faibles
  • Positions vendeuses élevées (20.37%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
27,52 €
-3.77% vs. cours
MM 200 jours
28,25 €
-6.23% vs. cours
Sous le plus haut 52s
−29.6%
37,62 €
Au-dessus du plus bas 52s
+32.3%
20,02 €

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

Risque de marché (Bêta)
0.68 · Défensive
Évolue moins que le marché global
Positions vendeuses
20.37% · Élevé
% du flottant vendu à découvert

The data points to relatively defensive market behavior, elevated short interest (20.37%).

Trading Data

50-Day MA: 27,52 €
200-Day MA: 28,25 €
Volume: 2,631,177
Avg. Volume: 2,176,787
Short Ratio: 10.03
P/B Ratio: 5.46x
Debt/Equity:
Free Cash Flow: -154 611 488 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Viking Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut